Notably, the most favorable outcomes were seen for the anti-PD1/LAG3/CTLA4/TREM2 combination, with complete responses of 100% for MMRd CRC and 73% for MMRp CRC (Figure 4 B/D, Extended Figure 15). This evidence concerns the gene TREM2 and colorectal carcinoma.